Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Goodwill & Intangibles (2021 - 2026)

Indivior Pharmaceuticals has reported Goodwill & Intangibles over the past 6 years, most recently at $2.0 million for Q1 2026.

  • For Q1 2026, Goodwill & Intangibles fell 71.43% year-over-year to $2.0 million; the TTM value through Mar 2026 reached $2.0 million, down 71.43%, while the annual FY2025 figure was $2.0 million, 66.67% down from the prior year.
  • Goodwill & Intangibles for Q1 2026 was $2.0 million at Indivior Pharmaceuticals, roughly flat from $2.0 million in the prior quarter.
  • Over five years, Goodwill & Intangibles peaked at $232.0 million in Q1 2024 and troughed at $2.0 million in Q3 2025.
  • A 5-year average of $90.0 million and a median of $13.0 million in 2023 define the central range for Goodwill & Intangibles.
  • Biggest five-year swings in Goodwill & Intangibles: grew 10.55% in 2024 and later tumbled 98.96% in 2025.
  • Year by year, Goodwill & Intangibles stood at $70.0 million in 2022, then crashed by 81.43% to $13.0 million in 2023, then crashed by 53.85% to $6.0 million in 2024, then plummeted by 66.67% to $2.0 million in 2025, then changed by 0.0% to $2.0 million in 2026.
  • Business Quant data shows Goodwill & Intangibles for INDV at $2.0 million in Q1 2026, $2.0 million in Q4 2025, and $2.0 million in Q3 2025.